Menactra IM Injection
Meningococcal A C Y and W-135 diphtheria conjugate vaccine
0.5 ml/vial
Synovia Pharma PLC.
| Pack size | 0.5 ml vial |
|---|---|
| Unite Price | 3,803.94 BDT |
Indications
Menactra IM Injection is used for:
To prevent invasive, meningococcal disease
Adult Dose
Meningococcal Vaccination
Indicated active immunization to prevent invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, Y, and W-135 in high risk adults
0.5 mL IM inj as single dose.
Primary vaccination Individual 2-55 yr Given as single dose. Childn 9-23 mth 2-dose series at least 3 mth apart.
Booster vaccination Individual 15-55 yr at continued risk for meningococcal disease Single booster dose, at least 4 yr have elapsed since prior dose.
Child Dose
Meningococcal Vaccination
Indicated active immunization to prevent invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, Y, and W-135 in high risk adults
0.5 mL IM inj as single dose.
Primary vaccination Individual 2-55 yr Given as single dose. Childn 9-23 mth 2-dose series at least 3 mth apart.
Booster vaccination Individual 15-55 yr at continued risk for meningococcal disease Single booster dose, at least 4 yr have elapsed since prior dose.
Renal Dose
Administration
IM Administration
Contra Indications
Hypersensitivity to the vaccine or after previous inj. Postpone vaccination in case of moderate or severe febrile or acute disease.
Precautions
Hypersensitivity. Not to be inj IV, SC or intradermally. Guillain-Barre syndrome; thrombocytopenia or bleeding disorders. Immunocompromised patients including those receiving immunosuppressant therapy. Syncope. Complement deficiency. Pregnancy & lactation. Not to be used in infants <9 mth. Elderly >55 yr.
Pregnancy-Lactation
Pregnancy category: C
Lactation: Unknown whether distributed in breast milk; use caution
Interactions
Reduced immune response w/ immunosuppressive therapies eg, irradiation, antimetabolites, alkylating agents, cytotoxic drugs, corticosteroids.
Side Effects
Side effects of Meningococcal A C Y and W-135 diphtheria conjugate vaccine :
>10%
Tenderness at injection site
Erythema
Swelling
Irritability
Abnormal crying
Drowsiness
Appetite loss
Induration
Vomiting
Fever
Malaise
Headache
Mode of Action
Presence of bacteriocidal anti-capsular meningococcal antibodies associated with protection from invasive meningococcal disease
Meningococcal serogroup A, C, Y and W-135 capsular polysaccharide antigens individually conjugated to diphtheria toxoid protein carrier
Induces production of bactericidal antibodies directed against the capsular polysaccharides of serogroups A, C, Y and W-135
Note
Menactra 0.5 ml/vial IM Injection generic name is Meningococcal A C Y and W-135 diphtheria conjugate vaccine. Menactra 0.5 ml/vial IM Injection is manufactured by Synovia Pharma PLC.Menactra is availble in all over Bangladesh.
Mes BD drug index information on Menactra IM Injection is not intended for diagnosis, medical advice or treatment; neither intended to be a substitute for the exercise of professional judgment.